Brooklyn Immunotherapeutics Inc
Change company Symbol lookup
Select an option...
BTX Brooklyn Immunotherapeutics Inc
SBCF Seacoast Banking Corporation of Florida
MSSAU Metal Sky Star Acquisition Corp
SDGR Schrodinger Inc
GPC Genuine Parts Co
VENA Venus Acquisition Corp
VECO Veeco Instruments Inc
IGTAU Inception Growth Acquisition Ltd
BAC-K Bank of America Corp
FAX abrdn Asia-Pacific Income Fund Inc
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Biotechnology |
Company profile

Brooklyn ImmunoTherapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing cytokine-based therapies for treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. Its lead product candidate, IRX-2, is a cytokine therapy, to treat patients with head and neck cancer. IRX-2 is a mixed, human-derived cytokine product with multiple active constituents including Interleukin-2 (IL2) and other key cytokines, which restore immune function suppressed by the tumor, thus enabling the immune system to attack cancer cells. The Company also has multiple cell and gene-editing therapies in preclinical development for various indications, including acute respiratory distress syndrome, solid tumor indications, as well as in vivo gene-editing therapies for rare genetic diseases. Its subsidiaries include Brooklyn ImmunoTherapeutics LLC, Novellus, Inc. and Novellus Therapeutics, Ltd.

Closing Price
$0.2303
Day's Change
-0.0319 (-12.17%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.2993
Day's Low
0.2303
Volume
(Heavy Day)
Volume:
1,727,500

10-day average volume:
815,612
1,727,500

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Global Blood Therapeutics, Inc. (Nasdaq - GBT)

10:58 am ET August 8, 2022 (Globe Newswire) Print

Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Global Blood Therapeutics, Inc. ("GBT" or the "Company") (Nasdaq - GBT) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the Company's agreement to be acquired by Pfizer Inc. (NYSE - PFE). Under the terms of the merger agreement, Pfizer will acquire GBT for $68.50 per share in cash for each outstanding share of common stock held for a total enterprise value of approximately $5.4 billion, including debt and net of cash acquired.

The investigation concerns whether the GBT Board breached its fiduciary duties to shareholders by failing to conduct a fair process, and whether Pfizer is paying too little for the Company. For example, the deal consideration is below the 52-week high of $73.02 for the Company's shares.

If you own shares of GBT stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman, Esquire at Brodsky & Smith, Two Bala Plaza, Suite 805, Bala Cynwyd, PA 19004, visit https://www.brodskysmith.com/cases/global-blood-therapeutics-inc-nasdaq-gbt/, or call toll free 855-576-4847.

Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.

https://ml.globenewswire.com/media/aeea7200-7231-49dd-b4ba-ec680464b28c/small/brodsky-smith-logo-png-png.png

https://ml.globenewswire.com/media/aeea7200-7231-49dd-b4ba-ec680464b28c/small/brodsky-smith-logo-png-png.png

comtex tracking

COMTEX_411848052/2010/2022-08-08T10:58:31

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.